Budesonide novolizer
PreclinicalSmall molecule
Budesonide novolizer is one of 32 small molecule programs targeting Chronic Cough. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
31
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
48 competitors in Chronic Cough
#DrugCompanyPhaseTrials
1Singulair
OOrganon and Co
Approved
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Nucala
GGlaxo Dba Glaxosmithkline
Approved
Nexium
DDexcel Pharma Technologies Ltd.
Approved
Aspercreme Warming
AAveritas Pharma, Inc.
Approved
Quietus
Merck & Co.Phase 2
Prilosec
DDexcel Pharma Technologies Ltd.
Phase 3
Indocin
LLife Extension Foundation Inc.
Phase 3
Elavil
AstraZenecaPhase 2
Cymbalta
Alnylam PharmaceuticalsPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Chronic Cough1 trial
Predictive Factors in Response to Inhaled Corticoids in Chronic Cough
Unknown status·CCliniques universitaires Saint-Luc- Université Catholique de Louvain·N/A·NCT02715167·100 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Budesonide novolizer. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details